Trial Profile
A Phase II Study Of KOS-862 (Epothilone D), Administered Intravenously Weekly For 3 Weeks Every 4 Weeks, In The Second-Line Treatment Of Patients With Advanced Or Metastatic Colorectal Carcinoma (CRC)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Epothilone D (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 06 Aug 2007 Status change from in progress to completed
- 15 Oct 2005 New trial record.